ClinicalTrials.gg
TerminatedNCT06929260Updated Jul 24, 2026

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

A Phase 1 interventional study of Ceralasertib and Drug X in Advanced Solid Tumours, sponsored by AstraZeneca. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Why this study was terminated
The study terminated because the clinical development programme for Ceralasertib has been discontinued.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study aims to assess the effect of ceralasertib on the pharmacokinetics (PK) of Drug X, Drug Y and Drug Z in participants with advanced solid tumours.

Read the detailed description

This is an open-label, 3-period fixed-sequence study. The study will comprise of -

  • Screening Visit (Visit 1)
  • Period 1 (Visit 2)
  • Period 2 (Visit 3)
  • Period 3 (Visit 4)
  • Follow-up Visit (Visit 5)

A wash-out period of no less than 48 hours in each period.

02

Conditions studied

  • Advanced Solid Tumours

Keywords

  • Pharmacokinetics
  • Drug-drug interactions
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented locally advanced or solid tumour(s) of non-small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer or prostate cancer at Screening.
  • Performance Status (ECOG PS) of 0 or 1 with no deterioration over the 2 weeks prior to dosing.
  • Ability to swallow and retain oral medication.
  • Minimum ≥ 12 weeks in the opinion of the Investigator.
  • Adequate organ and marrow function during Screening.
  • Body weight > 30 kg and no cancer-associated cachexia.
  • use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ataxia telangiectasia (ATR).
  • History of another primary except for:

    1. Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of the study intervention and of low potential risk for recurrence.
    2. Basal cell carcinoma of the skin.
    3. Curatively treated in situ cancer of the cervix.
    4. Ductal carcinoma in situ.
    5. Curatively treated lymphomas (without bone marrow involvement).
    6. Squamous cell carcinoma of the skin or lentigo maligna that has undergone potentially curative therapy.
    7. Adequately treated carcinoma in situ without evidence of disease.
  • History of .
  • History of myelodysplastic syndromes (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML (as determined by prior diagnostic investigation).
  • Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention.
  • Spinal cord compression or for at least 4 weeks prior to start of study intervention unless asymptomatic and stable.
  • Persistent toxicities, with the exception of alopecia and vitiligo, caused by previous anti-cancer therapy.
  • Participants with any known predisposition to bleeding.
  • nausea and vomiting, chronic gastrointestinal diseases associated with diarrhoea, or previous significant bowel resection, with sequelae that would preclude adequate absorption of ceralasertib.
  • Any of the following cardiac criteria or cardiovascular diseases -

    1. Any clinically important abnormalities in rhythm, conduction, or morphology of resting .
    2. Any factors that increase the risk of arrhythmic events such as heart failure, hypokalaemia, congenital long syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age.
    3. Participants at risk of brain perfusion problems.
    4. Participants with relative hypotension or uncontrolled hypertension requiring clinical intervention.
    5. Hypertensive heart disease with significant left ventricular hypertrophy or clinically significant valvular heart disease.
    6. History of atrial or ventricular arrhythmia requiring treatment.
    7. or stroke within 6 months prior to Screening.
  • Any participant with active infection requiring systemic antibiotics, antifungal or antiviral drugs.
  • Participants with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or active infection requiring systemic antibiotics, antifungal or antiviral drugs.
  • Any prior treatment with an ATR inhibitor or checkpoint kinase inhibitor.
  • Any concomitant treatment of central nervous system depressants, opioids, and centrally acting anti-hypertensive agents.
  • Receipt of the last dose anti-cancer therapy within 4 weeks or 5 half-lives prior to the first dose of ceralasertib, whichever is shorter.
  • Concomitant use of proton pump inhibitors, histamine H2 receptor antagonists, and other anti-acid agents.
  • Palliative radiotherapy with a limited field of radiation within 2 weeks.
  • Receiving or intend to receive any prescription or non-prescription drugs within 7 days or 5 half-lives before first dose of study intervention.
  • Use of tobacco- or nicotine-containing products within 3 months prior to check-in or history of drug or alcohol abuse.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Ceralasertib, Drug X, Drug Y and Drug Z

    Participants will receive ceralasertib twice daily (BD) from Day 1 to Day 7. Participants will also receive a single dose of Drug X on Day 5 and Day 22. Similarly, a single dose of Drug Y and Drug Z on Day 7 and Day 28.

    Drug: Ceralasertib · Drug: Drug X · Drug: Drug Y · Drug: Drug Z

Interventions

  • Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.

    Also known as: AZD6738

  • DrugDrug X

    Participants will receive a single dose of Drug X on Day 5 and Day 22.

  • DrugDrug Y

    Participants will receive a single dose of Drug Y on Day 7 and Day 28.

  • DrugDrug Z

    Participants will receive a single dose of Drug Z on Day 7 and Day 28.

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time 0 to infinity (AUCinf)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

  2. Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

  3. Maximum observed concentration (Cmax)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

  4. Plasma terminal elimination half-life (plasma t1/2λz)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

  5. Terminal elimination rate constante (λz)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

  6. Time to Reach Maximum Concentration Following Drug Administration (tmax)

    To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.

    Time frame: From Day 5 to Day 30

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of ceralasertib.

    Time frame: From Screening to follow up visit, for up to 65 days

  2. Trough concentrations of ceralasertib.

    To assess ceralasertib steady state.

    Time frame: Day 4 to Day 7

07

Study locations

1 site
  • Research Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST /Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Oct 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 16, 2025
StartActual
May 21, 2025
Primary completionActual
Oct 15, 2025
CompletionActual
Dec 18, 2025
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929260
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
May 21, 2025
Primary completion
Oct 15, 2025
Completion
Dec 18, 2025
Last update
Jul 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion